Form 4: Personalis CFO Aaron Tachibana Executes Stock Option Plan

CFO and COO Aaron Tachibana exercised options and sold 38,799 shares of Personalis, Inc. common stock under a 10b5-1 plan.

Summary

• Aaron Tachibana, CFO and COO of Personalis, Inc., exercised options to acquire 38,799 shares at a price of $9.16 per share.
• Following the acquisition, the reporting person sold the same number of shares (38,799) at a weighted average price of $11.58 per share.
• The transactions were executed on May 29, 2026, pursuant to a Rule 10b5-1 trading plan adopted on August 7, 2025.
• The sale price for the shares ranged from $11.50 to $11.71 per share.
• Post-transaction, the reporting person retains beneficial ownership of 198,833 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents standard executive financial management rather than a reaction to company-specific news.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.
• The reporting person maintains a significant remaining equity stake of 198,833 shares.

Negatives

• The transaction represents a divestment of shares by a key executive, which may be perceived as a reduction in direct exposure to the company's future performance.

Risks

• The reporting person's future financial interest in the company is reduced by the sale of these shares.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person confirmed that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on August 7, 2025.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard practice for executives to manage personal liquidity and diversify portfolios, and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate executives to avoid potential conflicts of interest or allegations of insider trading.
• The volume of shares sold is consistent with typical executive compensation liquidation patterns for mid-cap biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was conducted via a pre-established, automated trading plan.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Personalis, PSNL, Insider Trading, Form 4, CFO, Equity Compensation, Rule 10b5-1